# NRG Promethean (NCT05053152)

> Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

No report yet. It can be ordered.

- Drugs tested: relugolix
- Indication: oligometastatic prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05053152
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Ductal Adenocarcinoma; Prostate Intraductal Carcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions: Biospecimen Collection; Bone Scan; Computed Tomography; Fluciclovine F18; Magnetic Resonance Imaging; Placebo Administration; Positron Emission Tomography; PSMA PET Scan; Relugolix; Stereotactic Body Radiation Therapy
- Enrollment: 194
- Primary outcome: Radiological progression-free survival (rPFS)

## Indexed commentary on NRG Promethean so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nrg-promethean-nct05053152